BMRN is an over $100 stock and big dogs own it. They got no time to post in a message board, which apply to any expensive stock as well. If you notice, most active message boards for stocks below $50, and the lower you go, the more active the message board. My two cents....
Sentiment: Strong Buy
Once you get there, don't bail out. Usually, it will take off from there. So many times, I buy a stock, it dips, I wait and hold and get out when I'm even. Learned my lesson with Netflix. Bought it when it dropped from 300's level to 90's, then it dropped to 50's level. Waited till it went up again, bailed out. It skyrocket to 700's and split 7 for 1 and now is a hundred some dollars. I'm not saying it is going to happen here, but you never know, Vjet could reach 20's or 30's level in a year or two. My two cents, and I'm sticking with it.
Today announcement after hour of the options exercise price of $32.11 per share is an indication of good news tomorrow. Good luck to all longs and believers in this company and its medications.
I guess that investors are bailing out based on a bird on hand is better than ten on a tree theory. I'm holding my shares anticipating news at any minutes to send it skyrocket. I believe we have a winner here based on families feed back on their kid progress.
Heck to the no, but the writing on the wall as they say. The stock behavior the last three weeks says it all. I'm in since mid 20's and I won't be out if it hits three digit either. A buyout or in its own, Serapta will reach there God willing.
Man, it seems like you all in here for all mighty dollar only. Money can't buy happiness. Just ask any family with a kid suffering of DMD.
Just 9 weeks in, this treatment looks like it is slowing down that progression.
"We've noticed that he's getting up faster. I'm not having to help him as much," says Ashley.
Total revenues increased 100.9% to kEUR 5,484 from kEUR 2,730
• Systems revenues increased 56.6% to kEUR 1,933 from kEUR 1,234
• Services revenues increased 137.4% to kEUR 3,551 from kEUR 1,496
• Gross margin was 33.5% compared to 31.5% in the prior year quarter
• Reaffirm full year 2015 revenue guidance